Glizid M is an oral antidiabetic medication used to control the blood glucose levels in diabetes mellitus. It may be used along with Insulin or other medicines in order to achieve better control over the blood sugar levels. Patients are advised to maintain a strict exercise and diet regimen along with this medicine to get the best possible effect.
Glizid-M contains Gliclazide + Metformin. Metformin belongs to the class of combinations of oral blood glucose lowering drugs. Used in the treatment of diabetes.
Glizid M is product of Panacea Drugs Pvt. Ltd. Panacea Biotec was set up in the year 1984 and got listed in 1995 as Panacea Biotec Ltd. Panacea Biotec is an Indian research-based pharmaceutical and health management company involved in research, manufacturing, and marketing of pharmaceutical formulations, vaccines, and natural products. It is one of the three largest biotech companies in India.
Panacea Biotec has five research centres across India that specialize in the fields of pharmaceuticals, biotechnology, natural products and biopharmaceutics.
Diabetes Mellitus commonly known as diabetes, is a metabolic disease that causes high blood sugar. The hormone insulin moves sugar from the blood into your cells to be stored or used for energy. With diabetes, your body either doesn’t make enough insulin or can’t effectively use the insulin it does make.
Untreated high blood sugar from diabetes can damage your nerves, eyes, kidneys, and other organs.
There are a few different types of diabetes:
Type 1 diabetes is an autoimmune disease. The immune system attacks and destroys cells in the pancreas, where insulin is made. It’s unclear what causes this attack. About 10 percent of people with diabetes have this type.
Type 2 diabetes occurs when your body becomes resistant to insulin, and sugar builds up in your blood.
As directed by physician
As directed by physician
Adverse Reactions/ Side Effects
Significant: Hypoglycaemia. Blood and lymphatic system disorders: Rarely, anaemia, leucopenia, thrombocytopenia, agranulocytosis, pancytopenia, haemolytic anaemia, erythrocytopenia.
Skin and subcutaneous tissue disorders: Rarely, rash, pruritus, urticaria, angioedema, erythema, maculopapular rashes, bullous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms.
Warnings and Precautions
Patient with risk factors of hypoglycaemia (e.g. malnourished, poorly compensated endocrine disorders, severe vascular disease), and with poor carbohydrate intake or imbalanced diet, stress-related states (e.g. trauma, infection, surgery), G6PD-deficiency. . Mild to moderate hepatic and renal impairment.
Patient Counselling This medicine may cause dizziness, drowsiness or loss of consciousness which may indicate a severe fall of blood sugar, if affected, do not drive or operate machinery. Adhere strictly to diabetic diet. Avoid severe or prolonged exercise.
Monitoring Parameters Monitor fasting blood glucose, glycosylated Hb based on response, signs and symptoms of hypoglycaemia.
Hypersensitivity to gliclazide, sulfonylureas or sulphonamides. Type 1 diabetes, diabetic pre-coma and coma, diabetic keto-acidosis. Severe renal and hepatic impairment. Concomitant use with miconazole Pregnancy and lactation.
Increased hypoglycaemic effect with phenylbutazone. May decrease metabolism with chloramphenicol. May enhance effect of anticoagulant agents (e.g. warfarin). tMay enhance hypoglycaemic effect with other antidiabetic agents (e.g. insulin, metformin, glucagon-like peptide-1 receptor agonists, acarbose, thiazolidinediones, dipeptidyl peptidase-4 inhibitors), β-blockers, fluconazole, salicylates, ACE inhibitors (e.g. captopril, enalapril), H2-receptor blockers, MAOIs, sulfonamides, quinolone antibiotics, clarithromycin, and other NSAIDs. Increased blood glucose levels with chlorpromazine, β-agonists (e.g. salbutamol, ritodrine), tetracosactrin, glucocorticoids, danazol.
Potentially Fatal: Increased hypoglycaemic effect and possible onset of hypoglycaemia, or coma with miconazole.
May lead to onset of hypoglycaemic coma or increase of hypoglycaemic effect, and disulfiram-like reaction with alcohol. Decreased serum concentration with St. John’s Wort.
Symptoms: Hypoglycaemic reactions with or without coma, convulsions or other neurological disorders. Management: Consider carbohydrate intake, or modification of diet and dose adjustment. Administration of rapid IV injection of 50 mL (20-30%) concentrated glucose solution, followed by continuous infusion of 10% diluted glucose solution. Close monitoring is recommended.
Store between 15-30°C.
Mechanism of Action
Gliclazide is an antidiabetic sulphonylurea. It increases insulin sensitivity at peripheral target sites by stimulating insulin release from the pancreatic β-cells and reducing insulin uptake and glucose output of the liver. It has haemovascular properties in which it decreases microthrombosis by restoring fibrinolysis with increase in tissue plasminogen activator (t-PA) activity, and by partial inhibition of platelet aggregation and adhesion.